Anti-tumor potential of 15,16-dihydrotanshinone I against breast adenocarcinoma through inducing G1 arrest and apoptosis

Biochemical Pharmacology

Volumn 74, Issue 11, 2007, Pages 1575-1586

  Tsai, Sun Lung ^a   Suk, Fat Moon ^b   Wang, Chun I ^c   Liu, Der Zen ^d   Hou, Wen Chi ^d   Lin, Pei Jung ^c   Hung, Ling Fang ^c   Liang, Yu Chih ^b,c  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

15,16 Dihydrotanshinone I; Apoptosis; Breast cancer; Caspase; Cell cycle; G1 arrest

Indexed keywords

15,16 DIHYDROTANSHINONE I; CASPASE 3; CASPASE 7; CASPASE 9; CASPASE INHIBITOR; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYCLIN E; PROTEIN BCL XL; PROTEIN P27; SALVIA MILTIORRHIZA EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER MODEL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPLEX KINAE ASSAY; MALE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BREAST NEOPLASMS; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOCHROMES C; G1 PHASE; HUMANS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR STRUCTURE; PHENANTHRENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35349017930     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.08.009     Document Type: Article

References (37)

1. Longo R., Torino F., and Gasparini G. Targeted therapy of breast cancer. Curr Pharm Des 13 (2007) 497-517
2. Bremer E., van Dam G., Kroesen B.J., de Leij L., and Helfrich W. Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol Med 12 (2006) 382-393
3. Delivani P., and Martin S.J. Mitochondrial membrane remodeling in apoptosis: an inside story. Cell Death Differ 13 (2006) 2007-2010
4. Gupta S. Molecular signaling in death receptor and mitochondrial pathways of apoptosis (Review). Int J Oncol 22 (2003) 15-20
5. Sartorius U., Schmitz I., and Krammer P.H. Molecular mechanisms of death-receptor-mediated apoptosis. Chembiochem 8 (2001) 20-29
6. Gupta S. Molecular steps of death receptor and mitochondrial pathways of apoptosis. Life Sci 69 (2001) 2957-2964
7. Kadowaki H., Nishitoh H., and Ichijo H. Survival and apoptosis signals in ER stress: the role of protein kinases. J Chem Neuroanat 28 (2004) 93-100
8. Szegezdi E., Fitzgerald U., and Samali A. Caspase-12 and ER-stress-mediated apoptosis: the story so far. Ann NY Acad Sci 1010 (2003) 186-194
9. Gogvadze V., Orrenius S., and Zhivotovsky B. Multiple pathways of cytochrome c release from mitochondria in apoptosis. Biochim Biophys Acta 1757 (2006) 639-647
10. Garrido C., Galluzzi L., Brunet M., Puig P.E., Didelot C., and Kroemer G. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ 13 (2006) 1423-1433
11. Adams J.M., and Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26 (2007) 1324-1337
12. van Delft M.F., and Huang D.C. How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res 16 (2006) 203-213
13. Antignani A., and Youle R.J. How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane?. Curr Opin Cell Biol 18 (2006) 685-689
14. Earnshaw W.C., Martins L.M., and Kaufmann S.H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68 (1999) 383-424
15. Salvesen G.S. Caspases and apoptosis. Essays Biochem 38 (2002) 9-19
16. Wang X., Morris-Natschke S.L., and Lee K.H. New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev 27 (2007) 133-148
17. Zhou L., Zuo Z., and Chow M.S. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45 (2005) 1345-1359
18. Xu J.K., Hiroshi K., Zheng J.J., Jiang T., and Yao X.S. Protective effect of tanshinones against liver injury in mice loaded with restraint stress. Yao Xue Xue Bao 41 (2006) 631-635
19. Lee P., Hur J., Lee J., Kim J., Jeong J., Kang I., et al. 15,16-Dihydrotanshinone I suppresses the activation of BV-2 cell, a murine microglia cell line, by lipopolysaccharide. Neurochem Int 48 (2006) 60-66
20. Choi H.S., Cho D.I., Choi H.K., Im S.Y., Ryu S.Y., and Kim K.M. Molecular mechanisms of inhibitory activities of tanshinones on lipopolysaccharide-induced nitric oxide generation in RAW 264.7 cells. Arch Pharm Res 27 (2004) 1233-1237
21. Lee S.Y., Choi D.Y., and Woo E.R. Inhibition of osteoclast differentiation by tanshinones from the root of Salvia miltiorrhiza Bunge. Arch Pharm Res 28 (2005) 909-913
22. Lee D.S., and Lee S.H. Biological activity of dihydrotanshinone I: effect on apoptosis. J Biosci Bioeng 89 (2000) 292-293
23. Chen C.H., Sheu M.T., Chen T.F., Wang Y.C., Hou W.C., Liu D.Z., et al. Suppression of endotoxin-induced proinflammatory responses by citrus pectin through blocking LPS signaling pathways. Biochem Pharmacol 72 (2006) 1001-1009
24. Liu J.D., Lin S.Y., Ho Y.S., Pan S., Hung L.F., Tsai S.H., et al. Involvement of c-Jun N-terminal kinase activation in 15-deoxy-Δ12,14-prostaglandin J2 and prostaglandin A1-induced apoptosis in AGS gastric epithelial cells. Mol Carcinogenesis 37 (2003) 16-24
25. Liang Y.C., Tsai S.H., Chen L., Lin-Shiau S.Y., and Lin J.K. Resveratrol-induced G2 arrest through inhibition CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem Pharmacol 65 (2003) 1053-1060
26. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., and Baldwin Jr. A.S. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19 (1999) 5785-5799
27. Zieve G.W., Turnbull D., Mullins J.M., and McIntoch J.R. Production of large numbers of mitotic mammalian cells by use of the reversible microtubule inhibitor nocodazole. Nocodazole accumulated mitotic cells. Exp Cell Res 126 (1980) 397-405
28. Peters G. The D-type cyclins and their role in tumorigenesis. J Cell Sci (Suppl) 18 (1994) 89-96
29. Sherr C.J. D-type cyclins. Trends Biochem Sci 20 (1995) 187-190
30. Sutherland R.L., and Musgrove E.A. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 9 (2004) 95-104
31. Buckley M.F., Sweeney K.J., Hamilton J.A., Sini R.L., Manning D.L., Nicholson R.I., et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 8 (1993) 2127-2133
32. Arber N., Hibshoosh H., Moss S.F., Sutter T., Zhang Y., Begg M., et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 110 (1996) 669-674
33. Sutter T., Doi S., Carnevale K.A., Arber N., and Weinstein I.B. Expression of cyclin D1 and E in human colon. J Med 28 (1997) 285-309
34. Baldassarre G., Belletti B., Bruni P., Boccia A., Trapasso F., Pentimalli F., et al. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J Clin Investig 104 (1999) 865-874
35. Bosserhoff A.K. Novel biomarkers in malignant melanoma. Clin Chim Acta 367 (2006) 28-35
36. Harper J.W. Protein destruction: adapting roles for Cks proteins. Curr Biol 11 (2001) R431-R435
37. Johnson D.G., and Walker C.L. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39 (1999) 295-312